techno-foxx
15 Aug 2018
Market growth [link]
techno-foxx
13 Aug 2018
Market growth GlobeNewswire News Room – 8 Aug 18 Chimeric Antigen Receptor Market to See Explosive 44.1% Annual Growth Through... Immunotherapy Treatment Advancements Fuels Rapid Expansion
d_gaser
11 Aug 2018
Share Holders Base has changed, as Vulpes reduces it's holding Shareholders It would appear from the new list of stock holders that our benefactor has been taking profits ,and you certainly cant blame him for that .What doe’s worry me is that he might leave the board now his holding has been sold, and Vulpes holding is now down to just 17.7%. I wonder if he is selling into any rise over £9,that would explain why OXB price slides once the £9 price has been breached .We have no idea how low he is going to take his holding, personally I hope he will stop selling now and allow the price to move north again before selling any more . I have not seen any RNS showing this change our share holder base .I know if private sales are made ,it doesn’t have to be reported ,but I thought any change is share holders % holding did ? BE HAPPY Dave NameEquities% Vulpes Investment Management Pte Ltd. 11,620,169.=17.7% M&G Investment Management Ltd. 11,176,513 .=17.0%. Aviva Investors Global Services Ltd. 4,131,75. =16.29%; Hargreaves Lansdown Asset Management Ltd. 2,682,540;=4.08% S Shah 2,048,000 ; =3.12% TD Direct Investing (Europe) Ltd. 1,927,593; = 2.93%; Hargreave Hale Ltd. 1,779,860; = 2.71%; Joy Group Ltd. 1,737,876 ; = 2.65%; European Investment Management Ltd. 1,495,240 = 2.28%; Novartis AG 1,415,560; 2.15%;
techno-foxx
08 Aug 2018
Stagering market manipulation and tree shake Just another thought, after the massive share consolidation could be after these big announcements and partnerships we have shortage of stock, big massive orders to fill and not enough stock, so are city boys gaming this with naked shorts to tree shake smaller investors out of this share? huge trades and share selling without reason points to this, but I stress just my opinion.
techno-foxx
07 Aug 2018
Stagering market manipulation and tree shake As I pointed out when OXB and their car-t US Approval did not just give the ok to the Car-T treatment but also to OXB gene delivery system, (living drug) at the time I pointed out this had been missed by the market, however this latest good news if I am correct will be the first few of many new deals. PS sorry for over posting, however this new ii board is a real nightmare to navigate.
techno-foxx
06 Aug 2018
Boehringer- Ingelhelm deal with OXB Financial Post – 6 Aug 18 Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial... INGELHEIM, Germany — Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC)—consisting of Imperial College London and the Universities of Oxford and Edinburgh—Imperial Innovatio…
techno-foxx
06 Aug 2018
Boehringer- Ingelhelm deal with OXB boehringer-ingelheim.com Partnership to Develop Gene Therapy for Cystic Fibrosis | Press Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
techno-foxx
06 Aug 2018
New partnership Boehringer-Ingelheim-UK-Cystic-Fibrosis-Gene-Therapy deal Imperial News Researchers partner with industry to develop ground-breaking gene therapy for CF... A new partnership bringing together academic and pharmaceutical expertise has been established to develop a gene therapy for cystic fibrosis patients.
techno-foxx
06 Aug 2018
New partnership Boehringer-Ingelheim-UK-Cystic-Fibrosis-Gene-Therapy deal techno-foxx: Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial… [link]
techno-foxx
06 Aug 2018
New partnership Boehringer-Ingelheim-UK-Cystic-Fibrosis-Gene-Therapy deal businesswire.com Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial... Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC)—consisting of Imperial College London and the Universities of Oxford and Ed
d_gaser
19 Jul 2018
Kymriah generates $28m ,exceeding exspectations ,and increases OXB Royalties taken from the daily up date from Barclays FTSE Intraday notice Wed 18 Jul 2018 (Sharecast News) - Oxford BioMedica could get a bumper royalty payment from Novartis after solid sales of Kymriah drug in the second quarter.Kymriah, which uses a patient’s own T-cells to fight cancer, generated revenue of $16m in the latest quarter, bringing first-half sales to $28m. Oxford BioMedica receives royalties from Novartis from Kymriah sales and bioprocessing revenues, as the London-listed company is the sole manufacturer of the lentiviral vector required for Kymriah’s production.With its vectors used in other undisclosed CAR-T cell therapy products, Oxford BioMedica expects to receive in excess of $100m from Novartis over the next three years, it said last month.Broker Peel Hunt said it believe the $28m Kymriah revenue from the second quarter is only derived from US sales in the initial paediatric acute lymphoblastic leukaemia indication, for which it had forecast $36m for the whole of 2018, therefore implying “significant upside†to its earlier assumptions. Peel Hunt also expects a further $90m from a second, larger indication for Kymriah DLBCL, for which Kymriah was given US FDA approval in May and received a positive opinion from Europe’s CHMP in both indications in June. “We note however that press reports at the time of the US DLBCL approval suggested that Novartis will match key competitor Gilead’s price point in that indication of c$370,000 per treatment, vs the $475,000 announced for the smaller ALL indication. In summary then, whilst the Q2 results from Novartis give reason to expect Kymriah could beat our full year in-market sales forecasts, we wait to see how the DLBCL and Europe launches progress before altering our forecasts,†analysts wrote. Kymriah-related revenue accounts for around two thirds of the broker’s £67m 2018 revenue forecast for OxfordBioMedica, with the remainder driven by milestones and other development revenues. BE HAPPY DAVE
highsnlows
17 Jul 2018
Why the fall in SP? The sp is still on a negative slope, why??? Is there any news out there? I’m on the Interactive Investor site and I can’t find where RNS’s are put. This new system is becoming tiresome. HnL
riverside_red
03 Jul 2018
Why the fall in SP? Crazy day. Could sell but couldn’t buy.
doc-lee
03 Jul 2018
Why the fall in SP? What is the reason for the marked drop in share price over the last few days? Is it profit-taking or something more serious?
techno-foxx
02 Jul 2018
EU regulation Pharmaphorum – 2 Jul 18 CAR-Ts close to EU approval, face further US price scrutiny - Pharmaphorum Revolutionary CAR-T cell therapies for blood cancer could be on the European market within a few months after they were given the green light by regulators – but they face further price scrutiny in the US.
